PARIS--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority): Date Total Total number of voting rights number of outstanding shares August 40, 552, Theoretical number of voting rights: 31, 083 40, 552, 083 2015 (including treasury shares)Number of real voting rights: 40, 510, 182 (without treasury shares) At August 31, 2015, the Company’s capital stands at €10,138,020.75. About Onxeo Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives. Key products at advanced development stage are: Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad®): Positive complete results of the Phase II trial in severe oral mucositis Beleodaq® (belinostat): registered in the US in 2nd line treatment of peripheral T-cell lymphoma For more information, visit the website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3 A %2F%2Fwww.onxeo.com&esheet=51173478&newsitemid=0&lan=en -US&anchor=www.onxeo.com&index=1&md5=906000def4c2565b63c524d38caa138a) Onxeo Judith Greciet, CEO j.greciet@onxeo.com Nicolas Fellmann, CFO n.fellmann@onxeo.com +33 1 45 58 76 00 or Caroline Carmagnol and Florence Portejoie +33 6 64 18 99 59 / +33 1 44 54 36 66 onxeo@alizerp.com
Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at August 31, 2015
| Source: Onxeo SA